{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:54:56Z","timestamp":1792068896287,"version":"4.4.0"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic &amp; Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bmc.2026.118811","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:46:53Z","timestamp":1790380013000},"page":"118811","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Rivastigmine-centered molecular hybridization strategies for multi-targeted intervention in Alzheimer's disease: Advances (2020\u20132026)"],"prefix":"10.1016","volume":"143","author":[{"given":"Nitin","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virendra Kumar","family":"Kushwaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gourav","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smriti","family":"Ojha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok Kumar","family":"Dash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gauri","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2026.118811_bb0005","article-title":"Alzheimer\u2019s Disease: Exploring the Landscape of Cognitive Decline","author":"Tenchov","year":"2024","journal-title":"Am. Chem. Soc."},{"issue":"24","key":"10.1016\/j.bmc.2026.118811_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25245789","article-title":"Comprehensive review on Alzheimer\u2019s disease: causes and treatment","volume":"25","author":"Breijyeh","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2026.118811_bb0015","doi-asserted-by":"crossref","unstructured":"Z. He et al., \u201cThe current status, trends, and challenges of Alzheimer's disease and other dementias in Asia (1990\u20132036),\u201d Front. Public Health, vol. 13, 2025, doi:https:\/\/doi.org\/10.3389\/fpubh.2025.1583339.","DOI":"10.3389\/fpubh.2025.1583339"},{"issue":"6","key":"10.1016\/j.bmc.2026.118811_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/neurolint17060092","article-title":"Global diseases deserve global solutions: Alzheimer\u2019s disease","volume":"17","author":"Twiss","year":"2025","journal-title":"Neurol. Int."},{"issue":"24","key":"10.1016\/j.bmc.2026.118811_bb0025","doi-asserted-by":"crossref","first-page":"5945","DOI":"10.1021\/jm049782n","article-title":"Design, synthesis, and biological evaluation of conformationally restricted rivastigmine analogues","volume":"47","author":"Bolognesi","year":"2004","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bmc.2026.118811_bb0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s13311-014-0313-y","article-title":"\u03b2-Amyloid peptides and amyloid plaques in Alzheimer\u2019s disease","volume":"12","author":"Gouras","year":"2015","journal-title":"Neurotherapeutics"},{"issue":"10","key":"10.1016\/j.bmc.2026.118811_bb0035","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","article-title":"The amyloid-\u03b2 pathway in Alzheimer\u2019s disease","volume":"26","author":"Hampel","year":"2021","journal-title":"Mol. Psychiatry"},{"issue":"21","key":"10.1016\/j.bmc.2026.118811_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232112841","article-title":"Phosphorylated tau in Alzheimer\u2019s disease and other tauopathies","volume":"23","author":"Rawat","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bmc.2026.118811_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.617588","article-title":"Mitochondrial dysfunction and oxidative stress in Alzheimer\u2019s disease","volume":"13","author":"Misrani","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.bmc.2026.118811_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2025.102713","article-title":"Mitochondrial dysfunction in Alzheimer\u2019s disease","volume":"107","author":"D\u2019Alessandro","year":"2025","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.bmc.2026.118811_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/726954","article-title":"Metal Dyshomeostasis and inflammation in Alzheimer\u2019s and Parkinson\u2019s diseases: possible impact of environmental exposures","volume":"2013","author":"Myhre","year":"2013","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.bmc.2026.118811_bb0060","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.cotox.2021.03.008","article-title":"Metal toxicity and neuroinflammation","volume":"26","author":"Bondy","year":"2021","journal-title":"Curr Opin Toxicol"},{"issue":"9","key":"10.1016\/j.bmc.2026.118811_bb0065","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/j.jmb.2019.01.018","article-title":"Metal toxicity links to Alzheimer\u2019s disease and neuroinflammation","volume":"431","author":"Huat","year":"2019","journal-title":"J. Mol. Biol."},{"issue":"3","key":"10.1016\/j.bmc.2026.118811_bb0070","doi-asserted-by":"crossref","first-page":"972","DOI":"10.4103\/NRR.NRR-D-24-01054","article-title":"Potential common pathogenesis of several neurodegenerative diseases","volume":"21","author":"Fan","year":"2026","journal-title":"Neural Regen. Res."},{"issue":"20","key":"10.1016\/j.bmc.2026.118811_bb0075","doi-asserted-by":"crossref","first-page":"8881","DOI":"10.1021\/acs.jmedchem.9b00017","article-title":"Rational Design of Multitarget-Directed Ligands: strategies and emerging paradigms","volume":"62","author":"Zhou","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2026.118811_bb0080","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jconrel.2024.01.047","article-title":"Alzheimer\u2019s disease current therapies, novel drug delivery systems and future directions for better disease management","volume":"367","author":"Singh","year":"2024","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.bmc.2026.118811_bb0085","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1212\/01.CON.0000429180.60095.d0","article-title":"Alzheimer disease pharmacologic treatment and treatment research","volume":"19","author":"Schneider","year":"2013","journal-title":"Continuum (N. Y)."},{"issue":"15","key":"10.1016\/j.bmc.2026.118811_bb0090","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.2165\/11595870-000000000-00000","article-title":"Current and emerging drug treatment options for Alzheimer\u02bcs disease","volume":"71","author":"Herrmann","year":"2011","journal-title":"Drugs"},{"issue":"1\u20132","key":"10.1016\/j.bmc.2026.118811_bb0095","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.brainres.2005.08.039","article-title":"Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer\u2019s plaques and tangles","volume":"1060","author":"Eskander","year":"2005","journal-title":"Brain Res."},{"issue":"2","key":"10.1016\/j.bmc.2026.118811_bb0100","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2147\/nedt.2007.3.2.211","article-title":"Rivastigmine in the treatment of patients with Alzheimer\u2019s disease","volume":"3","author":"M\u00fcller","year":"2007","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"9","key":"10.1016\/j.bmc.2026.118811_bb0105","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1080\/14737175.2025.2527211","article-title":"An overview of the rivastigmine 13.3 mg\/24h transdermal patch as a treatment option for Alzheimer\u2019s disease","volume":"25","author":"Fortea","year":"2025","journal-title":"Expert. Rev. Neurother."},{"issue":"1","key":"10.1016\/j.bmc.2026.118811_bb0110","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41392-024-01911-3","article-title":"Recent advances in Alzheimer\u2019s disease: mechanisms, clinical trials and new drug development strategies","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bmc.2026.118811_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.116742","article-title":"Advancements in the development of multi-target directed ligands for the treatment of Alzheimer\u2019s disease","volume":"61","author":"Kumar","year":"2022","journal-title":"Bioorg. Med. Chem."},{"issue":"8","key":"10.1016\/j.bmc.2026.118811_bb0120","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.1021\/acs.jmedchem.1c00048","article-title":"Sustainable drug discovery of multi-target-directed ligands for Alzheimer\u2019s disease","volume":"64","author":"Rossi","year":"2021","journal-title":"J. Med. Chem."},{"issue":"May","key":"10.1016\/j.bmc.2026.118811_bb0125","article-title":"Recent developments in donepezil-based hybrid molecules as multi-target therapeutics for Alzheimer\u2019s disease: a paradigm shift beyond symptomatic treatment","volume":"181","author":"Kumar","year":"2026","journal-title":"Bioorg. Chem."},{"issue":"6","key":"10.1016\/j.bmc.2026.118811_bb0130","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.bmc.2019.01.025","article-title":"Anti-cholinesterase hybrids as multi-target-directed ligands against Alzheimer\u2019s disease (1998\u20132018)","volume":"27","author":"Mishra","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bmc.2026.118811_bb0135","doi-asserted-by":"crossref","DOI":"10.1039\/D6MD00462H","article-title":"Benzothiazole-driven molecular probes and therapeutics for neurodegenerative diseases: focus on amyloid-beta (a\u03b2), tau, and \u03b1-synuclein","author":"Kumar","year":"2026","journal-title":"RSC Med. Chem."},{"issue":"11","key":"10.1016\/j.bmc.2026.118811_bb0140","doi-asserted-by":"crossref","first-page":"7253","DOI":"10.1021\/acs.jmedchem.2c01824","article-title":"Explaining blood\u2013brain barrier permeability of small molecules by integrated analysis of different transport mechanisms","volume":"66","author":"Cornelissen","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2026.118811_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105941","article-title":"Rational drug design strategies for the development of promising multi-target directed indole hybrids as anti-Alzheimer agents","volume":"127","author":"George","year":"2022","journal-title":"Bioorg. Chem."},{"issue":"4","key":"10.1016\/j.bmc.2026.118811_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/molecules31040595","article-title":"Design and synthesis of tacrine\u2013coumarin hybrids via click chemistry as multifunctional cholinesterase inhibitors for the treatment of Alzheimer\u2019s disease","volume":"31","author":"Wang","year":"2026","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.bmc.2026.118811_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16020281","article-title":"New multitarget rivastigmine\u2013indole hybrids as potential drug candidates for Alzheimer\u2019s disease","volume":"16","author":"Bon","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bmc.2026.118811_bb0160","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2147\/CIA.S129145","article-title":"Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson&rsquo;s disease dementia","volume":"Volume 12","author":"Kandiah","year":"2017","journal-title":"Clin. Interv. Aging"},{"issue":"1","key":"10.1016\/j.bmc.2026.118811_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1592\/phco.20.1.1.34664","article-title":"Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer\u2019s disease","volume":"20","author":"Jann","year":"2000","journal-title":"Pharmacother"},{"issue":"20","key":"10.1016\/j.bmc.2026.118811_bb0170","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1021\/acschemneuro.5c00508","article-title":"Histidine focused covalent inhibitors targeting acetylcholinesterase: a computational pipeline for multisite therapeutic discovery in Alzheimer\u2019s disease","volume":"16","author":"Jaman","year":"2025","journal-title":"ACS Chem. Neurosci."},{"issue":"3","key":"10.1016\/j.bmc.2026.118811_bb0175","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/1570159X11311030006","article-title":"Acetylcholinesterase inhibitors: pharmacology and toxicology","volume":"11","author":"Colovic","year":"2013","journal-title":"Curr. Neuropharmacol."},{"issue":"1","key":"10.1016\/j.bmc.2026.118811_bb0180","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/biom10010040","article-title":"Alzheimer\u2019s disease pharmacotherapy in relation to cholinergic system involvement","volume":"10","author":"Stanciu","year":"2019","journal-title":"Biomolecules"},{"issue":"11","key":"10.1016\/j.bmc.2026.118811_bb0185","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1021\/bi020016x","article-title":"Kinetic and structural studies on the interaction of Cholinesterases with the anti-Alzheimer drug rivastigmine","volume":"41","author":"Bar-On","year":"2002","journal-title":"Biochemistry"},{"issue":"2","key":"10.1016\/j.bmc.2026.118811_bb0190","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1042\/BJ20111675","article-title":"Kinetics of Torpedo californica acetylcholinesterase inhibition by bisnorcymserine and crystal structure of the complex with its leaving group","volume":"444","author":"Bartolucci","year":"2012","journal-title":"Biochem. J."},{"key":"10.1016\/j.bmc.2026.118811_bb0195","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.cbi.2019.06.004","article-title":"Rate-limiting step in the decarbamoylation of acetylcholinesterases with large carbamoyl groups","volume":"308","author":"Rosenberry","year":"2019","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bmc.2026.118811_bb0200","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.abb.2018.08.006","article-title":"Decarbamoylation of acetylcholinesterases is markedly slowed as carbamoyl groups increase in size","volume":"655","author":"Venkatasubban","year":"2018","journal-title":"Arch. Biochem. Biophys."},{"issue":"8","key":"10.1016\/j.bmc.2026.118811_bb0205","doi-asserted-by":"crossref","DOI":"10.3390\/ijms27083637","article-title":"Emerging roles of rivastigmine derivatives bearing antioxidant motifs as multi-target agents for the management of neurodegenerative diseases","volume":"27","author":"Dias","year":"2026","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bmc.2026.118811_bb0210","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1385\/JMN:20:3:369","article-title":"Acetylcholinesterase: a multifaceted target for structure-based drug Design of Anticholinesterase Agents for the treatment of Alzheimer\u2019s disease","volume":"20","author":"Greenblatt","year":"2003","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.bmc.2026.118811_bb0215","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2019.10374","article-title":"Cholinesterase inhibitors as Alzheimer\u2019s therapeutics (review)","author":"Sharma","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.bmc.2026.118811_bb0220","doi-asserted-by":"crossref","unstructured":"Shaveta, S. Mishra, and P. Singh, \u201cHybrid molecules: the privileged scaffolds for various pharmaceuticals,\u201d Eur. J. Med. Chem., vol. 124, pp. 500\u2013536, 2016, doi:https:\/\/doi.org\/10.1016\/j.ejmech.2016.08.039.","DOI":"10.1016\/j.ejmech.2016.08.039"},{"issue":"1","key":"10.1016\/j.bmc.2026.118811_bb0225","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2147\/ciia.2007.2.1.17","article-title":"Rivastigmine in the treatment of Alzheimer\u2019s disease: an update","volume":"2","author":"Onor","year":"2007","journal-title":"Clin. Interv. Aging"},{"issue":"4","key":"10.1016\/j.bmc.2026.118811_bb0230","first-page":"285","article-title":"Carbamate group as structural motif in drugs: a review of carbamate derivatives used as therapeutic agents","volume":"71","author":"Mato\u0161evi\u0107","year":"2020","journal-title":"Arch. Ind. Hyg. Toxicol."},{"issue":"1","key":"10.1016\/j.bmc.2026.118811_bb0235","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s42004-019-0133-4","article-title":"Rivastigmine and metabolite analogues with putative Alzheimer\u2019s disease-modifying properties in a <i>Caenorhabditis elegans<\/i> model","volume":"2","author":"Dighe","year":"2019","journal-title":"Commun Chem"},{"key":"10.1016\/j.bmc.2026.118811_bb0240","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ejmech.2017.10.006","article-title":"Nature-based molecules combined with rivastigmine: a symbiotic approach for the synthesis of new agents against Alzheimer\u2019s disease","volume":"141","author":"Nesi","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmc.2026.118811_bb0245","doi-asserted-by":"crossref","DOI":"10.1177\/03946320241289013","article-title":"Enzyme ChE, cholinergic therapy and molecular docking: significant considerations and future perspectives","volume":"38","author":"Jovi\u010di\u0107","year":"2024","journal-title":"Int. J. Immunopathol. Pharmacol."},{"issue":"20","key":"10.1016\/j.bmc.2026.118811_bb0250","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27206894","article-title":"Evaluation of the key structural features of various butyrylcholinesterase inhibitors using simple molecular descriptors","volume":"27","author":"Mili\u010devi\u0107","year":"2022","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.bmc.2026.118811_bb0255","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1021\/acs.chemrev.8b00138","article-title":"Development of multifunctional molecules as potential therapeutic candidates for Alzheimer\u2019s disease, Parkinson\u2019s disease, and amyotrophic lateral sclerosis in the last decade","volume":"119","author":"Savelieff","year":"2019","journal-title":"Chem. Rev."},{"issue":"8","key":"10.1016\/j.bmc.2026.118811_bb0260","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1002\/ddr.22113","article-title":"Carbamate as a potential anti-Alzheimer\u2019s pharmacophore: a review","volume":"84","author":"Singh","year":"2023","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.bmc.2026.118811_bb0265","series-title":"Polypharmacology","first-page":"193","article-title":"Overcoming the challenges of multi-target-directed ligands for Alzheimer\u2019s disease","author":"Uliassi","year":"2025"},{"issue":"3","key":"10.1016\/j.bmc.2026.118811_bb0270","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1021\/jm7009364","article-title":"Multi-target-directed ligands to combat neurodegenerative diseases","volume":"51","author":"Cavalli","year":"2008","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bmc.2026.118811_bb0275","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.70131","article-title":"Multi-target drug Design in Alzheimer\u2019s disease treatment: emerging technologies, advantages, challenges, and limitations","volume":"13","author":"Hossain","year":"2025","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.bmc.2026.118811_bb0280","series-title":"Designing Multi-Target Drugs","first-page":"290","article-title":"Discovery of multi-target agents for neurological diseases via ligand design","author":"Bolognesi","year":"2012"},{"issue":"5","key":"10.1016\/j.bmc.2026.118811_bb0285","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1021\/acs.jmedchem.5b01674","article-title":"Discovery of highly selective and nanomolar carbamate-based butyrylcholinesterase inhibitors by rational investigation into their inhibition mode","volume":"59","author":"Sawatzky","year":"2016","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bmc.2026.118811_bb0290","doi-asserted-by":"crossref","DOI":"10.3390\/antiox11112167","article-title":"The link between oxidative stress, mitochondrial dysfunction and neuroinflammation in the pathophysiology of Alzheimer\u2019s disease: therapeutic implications and future perspectives","volume":"11","author":"Jurc\u0103u","year":"2022","journal-title":"Antioxidants"},{"issue":"12","key":"10.1016\/j.bmc.2026.118811_bb0295","doi-asserted-by":"crossref","DOI":"10.3390\/ph15121560","article-title":"Current pharmacotherapy and multi-target approaches for Alzheimer\u2019s disease","volume":"15","author":"Cheong","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"5","key":"10.1016\/j.bmc.2026.118811_bb0300","first-page":"733","article-title":"Targeting mitochondrial bioenergetics as a promising therapeutic strategy in metabolic and neurodegenerative diseases","volume":"45","author":"Bhatti","year":"2022","journal-title":"Biom. J."},{"issue":"9","key":"10.1016\/j.bmc.2026.118811_bb0305","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2174\/1568026616666160927154116","article-title":"Novel multitarget hybrid compounds for the treatment of Alzheimer\u2019s disease","volume":"17","author":"Michalska","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"issue":"7","key":"10.1016\/j.bmc.2026.118811_bb0310","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10071510","article-title":"Novel rivastigmine derivatives as promising multi-target compounds for potential treatment of Alzheimer\u2019s disease","volume":"10","author":"Vicente-Zurdo","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.bmc.2026.118811_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2026.110242","article-title":"Rationally designed phytochemical-derived carbamate hybrids unveiling potent inhibition of cholinesterase and amyloid-\u03b2 peptides","volume":"180","author":"Ghose","year":"2026","journal-title":"Bioorg. Chem."},{"issue":"17","key":"10.1016\/j.bmc.2026.118811_bb0320","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22179447","article-title":"Novel sulfonamide-based carbamates as selective inhibitors of BChE","volume":"22","author":"Magar","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bmc.2026.118811_bb0325","doi-asserted-by":"crossref","DOI":"10.1021\/acschemneuro.6c00170","article-title":"Rational design and evaluation of rivastigmine-based pleiotropic prodrugs for the treatment of Alzheimer\u2019s disease","author":"Travers-Lesage","year":"2026","journal-title":"ACS Chem. Neurosci."},{"issue":"1","key":"10.1016\/j.bmc.2026.118811_bb0330","doi-asserted-by":"crossref","DOI":"10.3390\/molecules29010072","article-title":"Rivastigmine\u2013bambuterol hybrids as selective butyrylcholinesterase inhibitors","volume":"29","author":"Wu","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2026.118811_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113735","article-title":"Novel cannabidiol\u2212carbamate hybrids as selective BuChE inhibitors: docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer\u2019s disease","volume":"223","author":"Jiang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmc.2026.118811_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115991","article-title":"Novel arylcarbamate-N-acylhydrazones derivatives as promising BuChE inhibitors: design, synthesis, molecular modeling and biological evaluation","volume":"32","author":"Yamazaki","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bmc.2026.118811_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112282","article-title":"N-alkylpiperidine carbamates as potential anti-Alzheimer\u2019s agents","volume":"197","author":"Ko\u0161ak","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"July","key":"10.1016\/j.bmc.2026.118811_bb0350","article-title":"Synthesis, molecular docking and molecular dynamics studies of novel tacrine-carbamate derivatives as potent cholinesterase inhibitors","volume":"115","author":"Ozten","year":"2021","journal-title":"Bioorg. Chem."},{"issue":"8","key":"10.1016\/j.bmc.2026.118811_bb0355","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2174\/1570159X19666201218103434","article-title":"Therapeutic potential of multifunctional derivatives of cholinesterase inhibitors","volume":"19","author":"Przyby\u0142owska","year":"2021","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.bmc.2026.118811_bb0360","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1616144","article-title":"Neurotherapeutics across blood\u2013brain barrier: screening of BBB-permeable and CNS-active molecules for neurodegenerative disease","volume":"16","author":"Mohan Kumar","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"September","key":"10.1016\/j.bmc.2026.118811_bb0365","article-title":"Rivastigmine structure-based hybrids as potential multi-target anti-Alzheimer\u2019s drug candidates","volume":"153","author":"Leuci","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"November 2024","key":"10.1016\/j.bmc.2026.118811_bb0370","article-title":"Discovery of novel hybrid tryptamine-rivastigmine molecules as potent AChE and BChE inhibitors exhibiting multifunctional properties for the management of Alzheimer\u2019s disease","volume":"283","author":"Shankar","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bmc.2026.118811_bb0375","first-page":"1","article-title":"Rivastigmine templates with antioxidant motifs\u2014a medicinal chemist\u2019s toolbox towards new multipotent AD drugs","volume":"14","author":"Dias","year":"2025","journal-title":"Antioxidants (Basel)"},{"issue":"21","key":"10.1016\/j.bmc.2026.118811_bb0380","doi-asserted-by":"crossref","first-page":"16855","DOI":"10.1039\/D5RA02267C","article-title":"Flavonoid carbamate hybrids: design, synthesis, and evaluation as multi-target enzyme inhibitors for Alzheimer\u2019s disease","volume":"15","author":"Tran","year":"2025","journal-title":"RSC Adv."},{"key":"10.1016\/j.bmc.2026.118811_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111958","article-title":"Apigenin-rivastigmine hybrids as multi-target-directed liagnds for the treatment of Alzheimer\u2019s disease","volume":"187","author":"Sang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"June","key":"10.1016\/j.bmc.2026.118811_bb0390","article-title":"Design, synthesis and biological evaluation of naringenin carbamate derivatives as potential multifunctional agents for the treatment of Alzheimer\u2019s disease","volume":"49","author":"Wu","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bmc.2026.118811_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112265","article-title":"Design, synthesis and biological evaluation of novel O-carbamoyl ferulamide derivatives as multi-target-directed ligands for the treatment of Alzheimer\u2019s disease","volume":"194","author":"Sang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"August 2024","key":"10.1016\/j.bmc.2026.118811_bb0400","article-title":"Exploiting the potential of rivastigmine-melatonin derivatives as multitarget metal-modulating drugs for neurodegenerative diseases","volume":"262","author":"Dias","year":"2025","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.bmc.2026.118811_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117175","article-title":"Design, synthesis and biological evaluation of new H2S-releasing rivastigmine derivatives as neuroprotective molecules","volume":"283","author":"Sestito","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"July","key":"10.1016\/j.bmc.2026.118811_bb0410","article-title":"Lead optimization of rivastigmine-like hybrids: impact of nitro group and halogen substitution on multi-target anti-Alzheimer\u2019s activity","volume":"141","author":"Leuci","year":"2026","journal-title":"Bioorg. Med. Chem."},{"issue":"2","key":"10.1016\/j.bmc.2026.118811_bb0415","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1007\/s12035-024-04333-y","article-title":"An expanded narrative review of neurotransmitters on Alzheimer\u2019s disease: the role of therapeutic interventions on neurotransmission","volume":"62","author":"Akyuz","year":"2025","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.bmc.2026.118811_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116071","article-title":"Design, synthesis and biological evaluation of carbamate derivatives incorporating multifunctional carrier scaffolds as pseudo-irreversible cholinesterase inhibitors for the treatment of Alzheimer\u2019s disease","volume":"265","author":"Liu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmc.2026.118811_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107152","article-title":"A comprehensive review of multi-target directed ligands in the treatment of Alzheimer\u2019s disease","volume":"144","author":"Pathak","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bmc.2026.118811_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113059","article-title":"Pleiotropic prodrugs: design of a dual butyrylcholinesterase inhibitor and 5-HT6 receptor antagonist with therapeutic interest in Alzheimer\u2019s disease","volume":"210","author":"Toublet","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bmc.2026.118811_bb0435","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2023.2231661","article-title":"Development of novel salicylic acid--donepezil--rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer\u2019s disease","volume":"38","author":"Zhou","year":"2023","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"December 2024","key":"10.1016\/j.bmc.2026.118811_bb0440","article-title":"Development of novel rivastigmine derivatives as selective BuChE inhibitors for the treatment of AD","volume":"157","author":"Li","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"9","key":"10.1016\/j.bmc.2026.118811_bb0445","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24098312","article-title":"Rivastigmine\u2013benzimidazole hybrids as promising multitarget metal-modulating compounds for potential treatment of neurodegenerative diseases","volume":"24","author":"Vicente-Zurdo","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bmc.2026.118811_bb0450","article-title":"Single molecule, dual actions: GSK-3\u03b2\/AChE dual inhibition for Alzheimer\u2019s disease","volume":"316, no. April","author":"Dong","year":"2026","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bmc.2026.118811_bb0455","doi-asserted-by":"crossref","DOI":"10.3390\/cimb47060417","article-title":"Neuroinflammation: mechanisms, dual roles, and therapeutic strategies in neurological disorders","volume":"47","author":"Garc\u00eda-Dom\u00ednguez","year":"2025","journal-title":"Curr Issues Mol Biol"},{"issue":"49","key":"10.1016\/j.bmc.2026.118811_bb0460","doi-asserted-by":"crossref","first-page":"30781","DOI":"10.1039\/D1RA03718H","article-title":"The recent development of donepezil structure-based hybrids as potential multifunctional anti-Alzheimer\u2019s agents: highlights from 2010 to 2020","volume":"11","author":"Kareem","year":"2021","journal-title":"RSC Adv."},{"issue":"August","key":"10.1016\/j.bmc.2026.118811_bb0465","article-title":"Discovery of novel substituted (Z)-N\u2032-hydroxy-3-(3-phenylureido)benzimidamide derivatives as multifunctional molecules targeting pathological hallmarks of Alzheimer\u2019s disease","volume":"280","author":"Shankar","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"April","key":"10.1016\/j.bmc.2026.118811_bb0470","article-title":"A novel carbamate-based hybrid derivative with anti-neuroinflammatory properties as a selective butyrylcholinesterase inhibitor for Alzheimer\u2019s disease therapy","volume":"161","author":"Liu","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bmc.2026.118811_bb0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2026.109887","article-title":"Design, synthesis, and biological evaluation of pyranone\u2013carbamate hybrids as selective butyrylcholinesterase inhibitors with anti-neuroinflammatory activity for Alzheimer\u2019s disease","volume":"176","author":"Liu","year":"2026","journal-title":"Bioorg. Chem."},{"issue":"29","key":"10.1016\/j.bmc.2026.118811_bb0480","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.2174\/0929867325666180111101843","article-title":"Multi-target directed drugs as a modern approach for drug design towards Alzheimer\u2019s disease: an update","volume":"25","author":"de Freitas Silva","year":"2018","journal-title":"Curr. Med. Chem."},{"issue":"10","key":"10.1016\/j.bmc.2026.118811_bb0485","doi-asserted-by":"crossref","first-page":"710","DOI":"10.4088\/JCP.v61n1001","article-title":"The new cholinesterase inhibitors for Alzheimer\u2019s disease, part 1: their similarities are different","volume":"61","author":"Stahl","year":"2000","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"10.1016\/j.bmc.2026.118811_bb0490","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22071192","article-title":"Assessment of enzyme inhibition: a review with examples from the development of monoamine oxidase and cholinesterase inhibitory drugs","volume":"22","author":"Ramsay","year":"2017","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.bmc.2026.118811_bb0495","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci11020184","article-title":"Anti-cholinesterase combination drug therapy as a potential treatment for Alzheimer\u2019s disease","volume":"11","author":"Amat-ur-Rasool","year":"2021","journal-title":"Brain Sci"},{"issue":"3","key":"10.1016\/j.bmc.2026.118811_bb0500","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0006-3223(00)01101-X","article-title":"Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer\u2019s disease","volume":"49","author":"Coyle","year":"2001","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.bmc.2026.118811_bb0505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5607\/en.2010.19.1.1","article-title":"Why do we need multifunctional neuroprotective and neurorestorative drugs for Parkinson\u2019s and Alzheimer\u2019s diseases as disease modifying agents","volume":"19","author":"Youdim","year":"2010","journal-title":"Exp Neurobiol"}],"container-title":["Bioorganic &amp; Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626002671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626002671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:38:04Z","timestamp":1792067884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089626002671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":101,"alternative-id":["S0968089626002671"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118811","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rivastigmine-centered molecular hybridization strategies for multi-targeted intervention in Alzheimer's disease: Advances (2020\u20132026)","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118811","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118811"}}